BETA-CELL FUNCTION IN PANCREATIC ADENOCARCINOMA

被引：36

作者：

BASSO, D

PLEBANI, M

FOGAR, P

DELFAVERO, G

BRIANI, G

MEGGIATO, T

PANOZZO, MP

FERRARA, C

DANGELI, F

BURLINA, A

机构：

[1] UNIV PADUA, IST MED LAB, LAB CENT, VIA GIUSTINIANI 2, I-35128 PADUA, ITALY

[2] UNIV PADUA, CATTEDRA GASTROENTEROL, I-35100 PADUA, ITALY

[3] UNIV PADUA, CATTEDRA MALATTIE RICAMBIO, I-35100 PADUA, ITALY

来源：

PANCREAS | 1994年 / 9卷 / 03期

关键词：

PANCREATIC ADENOCARCINOMA; DIABETES-MELLITUS; C-PEPTIDE; GLUCAGON;

D O I：

10.1097/00006676-199405000-00008

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

To evaluate beta-cell function in patients with pancreatic cancer, the glucagon stimulation test was performed in seven patients with pancreatic adenocarcinoma, seven patients with type I diabetes mellitus, seven patients with type II diabetes mellitus, and in seven healthy controls. C-peptide serum levels were determined before and after a 1-mg i.v. glucagon injection. Basal C-peptide values were normal or slightly increased in pancreatic cancer and type II diabetic patients and low in type I diabetic patients. Following glucagon stimulation, no significant increase was observed in C-peptide values of type I diabetics and pancreatic cancer patients, whereas significant increases occurred in controls and type II diabetics. It is concluded that the altered beta-cell function found in pancreatic cancer patients may lead to hyperglycemia, which is frequently associated with this tumor type.

引用

页码：332 / 335

页数：4